Dr. O’Regan on Biosimilar Education in Breast Cancer

Dr. O'Regan Discusses BELLE-3 Study in Breast CancerПодробнее

Dr. O'Regan Discusses Biosimilar Education in OncologyПодробнее

Dr. O'Regan on Biomarkers of Response to CDK4/6 Inhibitors in Breast CancerПодробнее

Dr. Gralow on the Science of Biosimilars and Implementation in Breast CancerПодробнее

Dr. O'Regan on Impact of Targeted Agents in HER2+ Breast CancerПодробнее

Dr. O'Regan on Emerging CDK4/6 Combinations in Breast CancerПодробнее

Dr. O'Regan on Future of Chemotherapy in Breast CancerПодробнее

Dr. O’Regan on the Status of Biosimilars in OncologyПодробнее

Dr. O'Regan on Biomarker Research in Breast CancerПодробнее

Dr. Dang on the Significance of the MYL-1401O Biosimilar in HER2-Positive Metastatic Breast cancerПодробнее

Dr. Hurvitz on Importance of Biosimilars in HER2+ Breast CancerПодробнее

What is Needed and What is the Role of Biosimilars?Подробнее

The Top 5 Biosimilars Articles for the Week of July 8Подробнее

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее

Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast CancerПодробнее

Biosimilar TrastuzumabПодробнее

Dr. Kalinsky Discusses Biosimilars in Breast CancerПодробнее

Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptinПодробнее

Colorectal Cancer: Addressing Barriers to Biosimilar UseПодробнее